Chromocell Therapeutics Corp CHRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CHRO is a good fit for your portfolio.
News
-
Chromocell Issues Letter to Stockholders from Chief Executive Officer
-
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
-
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
-
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
-
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
-
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
Trading Information
- Previous Close Price
- $1.74
- Day Range
- $1.70–1.93
- 52-Week Range
- $1.21–6.00
- Bid/Ask
- $1.70 / $2.50
- Market Cap
- $10.40 Mil
- Volume/Avg
- 15,299 / 31,382
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.chromocell.com
Valuation
|
Metric
|
CHRO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CHRO
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | −13.23 |
Quick Ratio
CHRO
Profitability
|
Metric
|
CHRO
|
|---|---|
Return on Assets (Normalized) | −8,935.07% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CHRO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zkpdnzdgxb | Tqpnf | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hflzzgbq | Rggxtnb | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rnqkpmhnc | Xcpbcm | $103.7 Bil | |
MRNA
| Moderna Inc | Twvhsvblb | Wzksr | $47.9 Bil | |
ARGX
| argenx SE ADR | Xzfrdsp | Sjlhg | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Fjnwbynv | Tzb | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zdnwphsgd | Qqmfrk | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hdplfggx | Vwxhbv | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bspdgvjgk | Kmytyvn | $12.8 Bil | |
INCY
| Incyte Corp | Prrwhdnc | Whyst | $12.1 Bil |